CG Oncology CEO Arthur Kuan leads the applause as the company rings the Nasdaq opening bell on Jan. 25, 2024 (Kyle LaHucik for Endpoints News)
Is CG Oncology’s IPO a benchmark for a better year in public offerings?
NEW YORK — CG Oncology rang the Nasdaq opening bell on Thursday morning, marking a rare sight for biotechs over the past two years as the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
